Steven Gerrard's daughter Lilly is expecting a baby with the son of a notorious Irish gangster who is back on the streets of ...

Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.

Eli Lilly ( LLY -6.59%) is the most valuable healthcare stock in the world, with a market capitalization of around $720 ...

If Eli Lilly has its way, this may be the future of obesity care. Eli Lilly makes some of the most powerful weight-loss drugs in the world. The company has pivoted dramatically over the past ...

DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating on January 21.Invest with Confidence: Follow ...

Eli Lilly forecasts $45 billion revenue for 2024, 32% higher than last year. Medicare changes and stocking issues impact the ...

In a report released yesterday, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price target of $1,020.00. Akash Tewari’s rating is based ...

While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly (NYSE: LLY) has two blockbuster weight loss drugs of its own: Mounjaro and Zepbound. Mounjaro and Zepbound are by ...

Eli Lilly (NYSE: LLY) is the most valuable healthcare stock in the world, with a market capitalization of around $720 billion. For a while, it looked like it might be on track to be the first ...